OKYO Pharma Ltd 6-K, filed Jun 9, 2022
OKYO Pharma Ltd (OKYO)
About this 6-K
OKYO Pharma Ltd filed this 6-K on June 9, 2022.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
June 2022
Commission File Number: 001-41386
OKYO Pharma LTD
(Exact Name of Registrant as Specified in Its Charter)
9th Floor
107 Cheapside
London
EC2V 6DN
(Address of registrant’s principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
On June 9, 2022, OKYO Pharma LTD (the “Company”) issued a news service announcement in the United Kingdom announcing a PDMR dealing.
The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| OKYO Pharma LTD | ||
| Date: June 9, 2022 | By: | /s/ Gary Jacob |
| Name: | Gary Jacob | |
| Title: | Chief Executive Officer | |
| 3 |
EXHIBIT INDEX
| Exhibit No. |
Description | |
| 99.1 | News Service Announcement, dated June 9, 2022 |
| 4 |
Exhibit 99.1
PDMR Dealing
London and New York, 9 June, 2022 – OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO), a bio-pharmaceutical company focused on developing an innovative approach to dry eye care and ocular pain, today announces that it has been notified that Willy Simon, a non-executive director, purchased an aggregate of 361,195 ordinary shares of no par value (“Ordinary Shares”) at a prices between £0.02679 and £0.0284 each.
| 1. | Details of PDMR / person closely associated | ||
| a) | Name | Willy Simon | |
| 2. | Reason for the notification | ||
| a) | Position / status | Non-executive director | |
| b) | Initial notification /amendment | Initial notification | |
| 3. | Details of the issuer | ||
| a) | Name | OKYO Pharma Limited | |
| b) | LEI | 213800VVN5CB56Y15A05 | |
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument | Ordinary Shares of no par value | |
| b) | Identification code of the Financial Instrument | ISIN for OKYO Pharma Limited GG00BD3FV870 | |
| c) | Nature of the transaction | Market Purchase | |
| d) | Price(s) and volume(s) | £0.0268 – 71,851
£0.0284 – 68,310
£0.0274 – 54,744
£0.0270 – 55,555
£0.0274 – 54,744
£0.02679 – 55,991
| |
| f) | Date of the transaction | 8 June 2022 | |
| g) | Place of the transaction | XLON | |
Enquiries:
| OKYO Pharma Limited | Gary S. Jacob, Chief Executive Officer Gabriele Cerrone, Non-Executive Chairman |
+44 (0)20 7495 2379 | ||
| Optiva
Securities Limited (Broker) |
Robert Emmet | +44 (0)20 3981 4173 |
Notes for Editors:
About OKYO
OKYO Pharma Limited (LSE: OKYO; NASDAQ: OKYO) is a life sciences company admitted to listing on the standard segment of the Official List of the UK Financial Conduct Authority and to trading on the main market for listed securities of London Stock Exchange plc. OKYO is focusing on the discovery and development of novel molecules to treat inflammatory dry eye diseases and chronic pain.
About OK-101
OK-101 is a lipidated chemerin peptide antagonist of the ChemR23 G-protein coupled receptor which is typically found on immunological cells of the eye responsible for the inflammatory response. OK-101 was developed using a membrane-anchored-peptide (MAP) Technology to produce a novel long-acting drug candidate for treating DED. OK-101 has been shown to produce anti-inflammatory activity in mouse models of DED and is designed to combat washout through the inclusion of the lipid ‘anchor’ contained in the candidate drug molecule to enhance the residence time of OK-101 within the ocular environment.
About Dry Eye Disease (DED)
Dry eye is a multifactorial disease that results in ocular discomfort and tear film instability that can lead to ocular surface damage. It is often a chronic problem, particularly in older adults, and is expected to become even more prevalent with the aging population and increased use of digital screens such as computers and smart phones. Despite new product approvals, dry eye disease (DED) remains a significant unmet medical need and is one of the leading causes for patient visits to eye care specialists. Novel therapies that improve the signs and symptoms of dry eye disease will be beneficial to dry eye patients.
For further information, please visit the Company’s website at www.okyopharma.com.